Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most ...

Curanex Pharmaceuticals Inc. CURX on Monday said that a recent patient case study may reinforce its strategic push into ...

Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ...

A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups. An analysis of ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Tumor cachexia is a serious syndrome affecting many cancer patients, who not only lose significant muscle mass and body weight, but also a considerable amount of quality of life and life expectancy.

Eating disorders are often thought of as body image disorders with symptoms of food restriction and purging. In most cases, the goal of these behaviors is to prevent weight gain. Not all eating ...

Cachexia is a paraneoplastic syndrome of unintentional adipose and muscle tissue wasting with severe impacts to functionality and quality of life. Although health inequities across minority and ...

The optimal therapy for anorexia and cachexia is curing the underlying cancer. [23] Unfortunately, this goal is often not attainable with currently available treatments. Thus, an integrated ...